Mefloquine for preventing malaria in pregnant women by González, Raquel et al.
Cochrane Database of Systematic Reviews
Mefloquine for preventing malaria in pregnant women
(Protocol)
González R, Boerma RS, Sinclair D, Aponte JJ, ter Kuile FO, Menéndez C
González R, Boerma RS, Sinclair D, Aponte JJ, ter Kuile FO, Menéndez C.
Mefloquine for preventing malaria in pregnant women.
Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD011444.
DOI: 10.1002/14651858.CD011444.
www.cochranelibrary.com
Mefloquine for preventing malaria in pregnant women (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
6ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iMefloquine for preventing malaria in pregnant women (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Mefloquine for preventing malaria in pregnant women
Raquel González1, Ragna S Boerma1, David Sinclair2, John J Aponte1, Feiko O ter Kuile3, Clara Menéndez1
1Barcelona Institute for Global Health, ISGlobal, Barcelona Ctr. Int. Heath Res. (CRESIB), Hospital Clínic-Universitat de Barcelona,
Barcelona, Spain. 2Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. 3Child & Reproductive
Health Group, Liverpool School of Tropical Medicine, Liverpool, UK
Contact address: Raquel González, ISGlobal, Barcelona Centre for International Health Research,CRESIB,Hospital Clinic-Universitat
de Barcelona, Barcelona, Spain. raquel.gonzalez@cresib.cat.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New, published in Issue 1, 2015.
Citation: González R, Boerma RS, Sinclair D, Aponte JJ, ter Kuile FO, Menéndez C. Mefloquine for preventing malaria in pregnant
women. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD011444. DOI: 10.1002/14651858.CD011444.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of mefloquine for preventing malaria in pregnant women. Specifically, to evaluate the:
• efficacy, safety and tolerability of mefloquine for preventing malaria in pregnant women.
• effect of HIV status, gravidity and ITN use on mefloquine efficacy.
B A C K G R O U N D
Description of the condition
Malaria is the most important parasitic disease worldwide and is
endemic in parts of Africa, Asia and South America. Pregnant
women are at a higher risk of malaria infection than non-preg-
nant women in the same age group, and are also at higher risk
of severe illness (Brabin 1983; Desai 2007). Malaria infection
during pregnancy, particularly the first or second pregnancy, is
also associated with adverse outcomes for both the mother (se-
vere anaemia) and the infant (low birth weight, neonatal mortal-
ity; Radeva-Petrova 2014, Ataide 2014; Menendez 2010; Steketee
2001; Schwarz 2008; Guyatt 2004).
To reduce the burden and consequences of malaria in pregnancy
(MiP), the World Health Organization (WHO) currently recom-
mends that pregnant women who live in moderate to high malaria
transmission areas in Africa i) sleep under an insecticide treated
net (ITN) (Gamble 2006) and ii) receive intermittent-preven-
tive treatment (IPT) with sulfadoxine-pyrimethamine (SP) at each
scheduled antenatal care visit (provided that the doses are at least
one month apart) (WHO 2013). IPT is a form of malaria chemo-
prevention that was tested and adopted as policy in response to
malaria parasites developing resistance to weekly prophylaxis with
chloroquine (WHO 2004). The long elimination half-life of SP
allowed intermittent dosing (at least amonth apart) while still pro-
viding prophylactic cover for the intervening weeks (White 2005).
IPT is therefore defined as the ’administration of a curative treat-
ment dose of an effective antimalarial drug at predefined intervals
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during pregnancy’ regardless of the presence or absence of current
infection (White 2005).
SP remains the drug used for IPT in pregnancy, even though
resistance to it is spreading rapidly in many parts of southern and
eastern Africa (Ter Kuile 2007; WHO 2012). This is spurring
researchers and policy makers to seek safe and effective alternatives
to SP.
Description of the intervention
Mefloquine (MQ) is a 4-methanolquinoline related to quinine. It
was originally developed by the USmilitary for preventingmalaria
in soldiers, but has also been widely used for preventing malaria
in travellers (Schlagenhauf 2010). Like SP, mefloquine has a long
elimination half-life of two to four weeks;in travellers, weekly dos-
ing at 250 mg is used (FDA 2004), while in pregnant women
monthly dosing at treatment doses is feasible.
Mefloquine was first investigated as a prophylactic treatment for
pregnant women in the 1990s. An observational study by Nosten
1999 raised concerns that mefloquine may be associated with an
increased risk of stillbirths, however this was not confirmed in
other trials (Nosten 1994; Steketee 1996). The safety of meflo-
quine in pregnancy has recently been considered in a systematic
review that concluded there is no evidence that mefloquine use
in pregnancy carries an increased risk for the foetus (Gonzalez
2014). The drug is known to be associated with a range of mild
side effects, such as vomiting, nausea and dizziness (Bardaji 2012;
Sevene 2010). Severe neuropsychiatric side effects have been de-
scribed and occur in about one in 10,000 travellers taking meflo-
quine as chemoprophylaxis (Steffen 1993). Studies conducted in
Beninese pregnant women found that dizziness and vomiting are
the most frequent adverse effects related to mefloquine given as
IPTin pregnancy (Briand 2009; Denoeud-Ndam 2012).
Resistance to mefloquine has been reported in multi-drug resis-
tance areas of Thailand (Carrara 2009; Nosten 2000), but it re-
mains rare in Africa (Aubouy 2007; MacArthur 2001; Oduola
1987).
How the intervention might work
Malaria chemoprevention is thought to work through the clear-
ance or suppression of asymptomatic malaria infections in the
mother and the placenta (White 2005). This reduction in malaria
parasitaemia may, however, be insufficient to justify recommen-
dations for widespread prophylactic prescriptions, without sub-
sequent benefits to clinically important outcomes in the mother
and her baby. These outcomes may include a reduction in malaria
episodes, a reduced risk of anaemia and improved birth weight, as
well as more substantive outcomes such as a reduction in severe
maternal illness or a lower mortality rate among mothers and in-
fants (see Figure 1).
Figure 1.
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The effects of malaria chemoprevention may depend on the local
malaria epidemiology. In highly endemic areas with stable trans-
mission, mothers may have partial immunity to malaria, causing
parasitaemia without clinical disease, but this can still produce
detrimental effects such as anaemia and low birth weights. In con-
trast, where malaria transmission is seasonal or unstable, natural
immunity may be lower and the main effects of chemoprevention
may be a reduction in clinical episodes or severe illness.
Primiparous women appear to be more at risk of adverse outcomes
of malaria in pregnancy than multiparous women. This is thought
to be due to women developing antibodies specific to placen-
tal-type parasites when exposed to Plasmodium falciparum during
their first pregnancy. These antibodies are thus already present for
subsequent pregnancies (Ataide 2014). This means multiparous
women can exert a more specific and efficient immune response
and so clear the infection at an earlier stage (Walker 2013).
Another potential effect modifier is HIV status (Menendez 2011).
Many malaria endemic areas also have a high prevalence of HIV
infection among pregnant women, which has been shown to in-
crease the risk ofmalaria infection (van Eijk 2003,Gonzalez 2012).
Compared with HIV-negative women, HIV-positive women are
more likely to carry malaria parasites in their blood, have higher
parasite densities, and have placental parasitaemia, anaemia and
malaria symptoms (Ayisi 2003; van Eijk 2002; van Eijk 2003).
This increased risk appears to be just the same for multigravidae
(women in their third pregnancy or higher) as for women in their
first or second pregnancy (van Eijk 2003).Heavy placental malaria
infection may also increase the risk of perinatal mother-to-child
transmission of HIV (Ayisi 2003).
The use of ITN during pregnancy has also been shown to have a
beneficial impact on pregnancy outcomes (reduced prevalence of
low birth rate, miscarriage and placental parasitaemia) in malaria-
endemic Africa (Gamble 2007) and could modify the effect of
IPT.
Why it is important to do this review
The WHO recommends IPT with SP for all pregnant women
who live in moderate to high malaria transmission areas in Africa
(WHO 2004; WHO 2013). However, studies have shown that
resistance to SP in some regions of Eastern Africa has been growing
rapidly over the past few years (Iriemenam 2012; Mockenhaupt
2008). Thus, there is an urgent need for other drugs with lower
resistance patterns to be assessed for their ability to preventmalaria
during pregnancy.
This review aims to evaluate the efficacy and safety of mefloquine
for preventing malaria in pregnant women. Based on these find-
ings, future guidelines on preventive agents for malaria could be
developed.
O B J E C T I V E S
To assess the effects of mefloquine for preventing malaria in preg-
nant women. Specifically, to evaluate the:
• efficacy, safety and tolerability of mefloquine for preventing
malaria in pregnant women.
• effect of HIV status, gravidity and ITN use on mefloquine
efficacy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized controlled trials.
To evaluate the safety of mefloquine in pregnancy we will also
include observational studies (such as non-randomized controlled
studies and uncontrolled case series) in order to obtain larger par-
ticipant samples.
Types of participants
Pregnant women of any gravidity and regardless of HIV status,
living in endemic malaria areas.
To evaluate the safety of mefloquine in pregnancy, we will also
include studies where mefloquine was used to prevent malaria in
pregnant women travelling to malaria endemic areas.
Types of interventions
Interventions
Mefloquine given to pregnant women as intermittent preventive
treatment or as chemoprophylaxis.
Controls
Placebo, no intervention, or an alternative drug regimen.
Types of outcome measures
• Maternal:
◦ Maternal peripheral parasitaemia during pregnancy
◦ Maternal peripheral parasitaemia at delivery
◦ Placental malaria*
◦ Mean haemoglobin and maternal anaemia (as defined
in the original studies) during pregnancy
◦ Mean haemoglobin and maternal anaemia at delivery
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◦ Clinical malaria episodes during pregnancy
• Fetal/infant:
◦ Cord blood parasitaemia
◦ Cord blood haemoglobin and anaemia (as defined in
the original studies)
◦ Mean birth weight
◦ Low birth weight prevalence (< 2500 g)
◦ Prematurity prevalence (<37 weeks of gestation)
◦ Neonatal morbidity in first 28 days of life
◦ Morbidity in first year of life
• Safety:
◦ Serious Adverse Events (SAEs)
⋄ Illnesses that were life threatening or required
hospitalization during pregnancy
⋄ Adverse pregnancy outcomes: spontaneous
abortions, stillbirths, congenital malformations
⋄ Maternal mortality
⋄ Perinatal, neonatal, infant mortality
◦ Tolerability
⋄ Frequency and severity of reported all-cause and
drug-related adverse effects
*Placental malaria diagnosed by histology, microscopy or any
method used in the included study. Figure 2 shows the relation
between the different outcomes.
Figure 2. Reproduced under the terms of a Creative Commons Licence from Radeva-Petrova 2014: Radeva-
Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in
endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database of Systematic Reviews
2014, Issue 10. Art. No.: CD000169. DOI: 10.1002/14651858.CD000169.pub3.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms and
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strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register; Central Register of Controlled Trials
(CENTRAL), published in The Cochrane Library; MEDLINE;
EMBASE; and LILACS. We will also search the Malaria in Preg-
nancy (MiP) Library (http://www.mip-consortium.org/resources/
index.htm), the WHO clinical trial registry platform, and the
metaRegister of Controlled Trials (mRCT) using ’mefloquine’,
’malaria’, and ’pregnan*’ as search terms.
Searching other resources
We will contact researchers working in the field for unpublished
data, confidential reports, and raw data of published trials. We
will also check the citations of all trials identified by the above
methods.
Data collection and analysis
Selection of studies
Two authors will independently screen all trials identified by the
search strategy (Appendix 1). Full text copies will be retrieved
for all trials deemed potentially relevant. Two authors will then
independently assess eligibility using a formbased on the inclusion
criteria. Disagreements will be resolved through discussion or by
consulting a third author. Any author that has participated in
trials that could be potentially meeting the inclusion criteria of
the review will not participate in the procedure to select studies
for inclusion.
Data extraction and management
Two authors will independently extract data using a data extrac-
tion form. We will extract data on trial characteristics, including
trial site, year, local malaria transmission estimates, antimalarial
resistance pattern of mefloquine and the comparator drug (where
possible), trialmethods, participants, interventions, doses andout-
comes.
We will extract the number of participants randomized and the
number analysed in the experimental and control arms for each
outcome. For dichotomous outcomes, we will extract the number
of participants experiencing the event and the number assessed
in each treatment group. For continuous outcomes, we will ex-
tract the arithmetic means, standard deviations for each treatment
group (where provided), and the number of participants assessed
in each group. We will also extract medians and ranges where pro-
vided.
Any author who has participated in any of the trials included in
the review will not participate in the data extraction or risk of bias
assessment.
Assessment of risk of bias in included studies
Two authors will independently assess the risk of bias for each
trial using the Cochrane Collaboration’s tool for assessing the risk
of bias (Higgins 2011). This approach assesses the risk of bias
across six domains: sequence generation, allocation concealment,
blinding, incomplete outcome data, selective outcome reporting,
and other potential biases (Higgins 2011). For each domain, we
will assign a judgment of low risk of bias, high risk of bias, or
unclear risk of bias. For observational studies, the risk of selection,
performance, attrition, detection and selective reporting biases will
be evaluated, following the guidelines of the Agency forHealthcare
Research and Quality (Viswanathan 2012).
Measures of treatment effect
Dichotomous outcomes will be presented using risk ratios (RR),
count outcomes will be presented as rate ratios (Rate R), and con-
tinuous outcomes will be presented as the mean difference (MD).
All measures of effect will be presented with 95% confidence in-
tervals (CI).
Unit of analysis issues
Trials includingmore than two comparison groupswill be split and
analysed as individual pair-wise comparisons. When conducting
a meta-analysis, we will ensure that participants and cases in the
placebo group are not counted more than once, by dividing the
placebo cases and participants evenly between the intervention
groups.
Dealing with missing data
We will aim to conduct the analysis according to the intention-to-
treat principle. However, when there was loss to follow up (or if
participants were excluded because they developed malaria para-
sitaemia after randomization and received antimalarial treatment),
a complete-case analysis will be used, such that participants for
whom no outcome was reported are excluded from the analysis.
This analysis assumes that the participants for whom an outcome
is available are representative of the original randomized patients.
Wewill conduct a sensitivity analysis as described below to evaluate
the robustness of this methodology. If data from the trial reports
are insufficient, unclear or missing, we will attempt to contact the
authors for additional information.
Assessment of heterogeneity
Wewill calculate the I2-statistic using values of 30% to 59%, 60%
to 89%, and 90% to 100% to denote moderate, substantial and
considerable levels of heterogeneity respectively.
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Assessment of reporting biases
Where possible, we will assess the risk of publication bias by con-
structing funnel plots and looking for asymmetry.
Data synthesis
Data will be analyzed using ReviewManager 5.3 (ReviewManager
(RevMan)). The primary analysis will be stratified by parity and
HIV status where possible. In the absence of heterogeneity, we will
use a fixed-effect model for themeta-analysis, and where moderate
heterogeneity is detected we will use a random-effects model.
Subgroup analysis and investigation of heterogeneity
Wewill investigate heterogeneity by conducting pre-specified sub-
group analysis to evaluate the contribution of differences in trial
characteristics such as risk of bias, geographical region, malaria
transmission pattern, antimalarial resistance, drug regimen, use of
ITNs, parity (para 0 to 1 versus multigravidae), HIV status (neg-
ative, positive, unknown), and trial methods.
Sensitivity analysis
We will conduct a sensitivity analysis to restore the integrity of the
randomization process and test the robustness of our results.
A C K N OW L E D G E M E N T S
The academic editor for this protocol is Dr Hasifa Bukirwa.
The editorial base for the Cochrane Infectious Diseases Group is
funded by UK aid from the UK Government for the benefit of
developing countries.
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A P P E N D I C E S
Appendix 1. Detailed search strategies
Search set CIDG Specialized
register
CENTRAL MEDLINE Embase LILACS
1 malaria Malaria ti, ab, MeSH Malaria ti, ab, MeSH Malaria ti, ab, Emtree malaria
2 Mefloquine OR Lar-
iam
Mefloquine ti, ab,
MeSH
Mefloquine ti, ab,
MeSH
Mefloquine ti, ab,
Emtree
Tafenoquine
3 Pregnan* Lariam ti, ab Lariam ti, ab Lariam ti, ab Lariam
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(Continued)
4 1 and 2 and 3 2 or 3 2 or 3 2 or 3 2 or 3
5 1 and 4 1 and 4 1 and 4 1 and 4
6 Pregnan* ti, ab Pregnan* ti, ab Pregnan* ti, ab Pregnan$
7 Pregnancy [Mesh] Pregnancy [Mesh] Pregnancy [Emtree] 5 and 6
8 6 or 7 6 or 7 6 or 7
9 5 and 8 5 and 8 5 and 8
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